Halozyme Therapeutics is a clinical-stage biopharmaceutical company founded in 1998 and headquartered in San Diego, California. The company specializes in the development of proprietary drug delivery technologies designed to improve the administration and performance of therapeutic agents. By leveraging its expertise in recombinant human hyaluronidase (rHuPH20), Halozyme seeks to enable subcutaneous delivery of injectable drugs that traditionally require intravenous infusion, thereby enhancing patient convenience and optimizing healthcare resource utilization.
The core of Halozyme’s platform is the Enhanze drug delivery technology, which transiently degrades hyaluronan in the extracellular matrix to facilitate dispersion and absorption of co-administered therapies. Halozyme has established strategic collaborations and licensing agreements with leading global biopharmaceutical companies, including Roche, Janssen and Pfizer, to develop subcutaneous formulations of established oncology, immunology and rare disease therapies. Notable products leveraging Enhanze technology include subcutaneous versions of trastuzumab (Herceptin Hylecta) and rituximab (Rituxan Hycela), as well as HyQvia for immune globulin replacement therapy.
In addition to its partnered products, Halozyme maintains an internal pipeline focused on novel therapeutic candidates and next-generation formulations. The company’s research efforts encompass oncology, metabolic disease and immuno-inflammatory conditions, supported by ongoing clinical trials and preclinical studies. Halozyme also continues to expand its Enhanze platform through process improvements and exploration of new indications, underscoring its commitment to advancing patient care through innovative drug delivery solutions.
Under the leadership of President and CEO Helen I. Torley, M.D., Halozyme operates research and development facilities in San Diego and manufacturing sites in Hayward, California. The company’s global operations and partnerships extend across North America, Europe and Asia, reflecting its ambition to bring transformative therapies to patients worldwide. Halozyme’s emphasis on strategic collaboration, technological innovation and patient-centric delivery positions it as a notable player in the biopharmaceutical industry.
AI Generated. May Contain Errors.